FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563674152> ?p ?o ?g. }

• W2563674152 endingPage "4903" @default.
• W2563674152 startingPage "4903" @default.
• W2563674152 abstract "Abstract Abstract 4903 Background Use of BCR-ABL TKIs (Tyrosine-Kinase inhibitors) is the standard therapy for chronic myeloid leukemia. Dasatinib at the dosage of 100 mg once daily (QD) has been registered as first-line treatment for chronic phase chronic myeloid leukemia (CML) because it has been shown to be able to elicit faster and deeper cytogenetic and molecular responses than imatinib 400 QD, preventing also some events of progression to advanced phases of the disease, that can still occur during the first 2–3 years of treatment with TKIs. This is likely to be related to the strength of BCR-ABL in inhibiting the BCR-ABL TK activity and to its capacity to inhibit many of the BCR-ABL mutant forms than can escape inhibition by imatinib. However, very little is at present known about the relationship existing between the plasma level of dasatinib and its intracellular concentration, as well as about the factors that can influence drug intracellular penetration. This could help in understanding the relationship existing between drug level and its effectiveness in individual patients, as well as it may potentially help to modulate drug level by dose adjustment, useful to prevent toxicity and unwanted side-effects that could limit the efficacy of this drug in CML treatment. Aim of our study were to perform quantification of dasatinib in human peripheral blood mononuclear cells (PBMC) and evaluated whether single-nucleotide polymorphisms (SNPs) in ABCB1 gene may work as predictors of dasatinib exposure. Materials and Methods Patients administered with dasatinib since at least 1 month were considered in the study. Sampling was performed after written informed consent was obtained in accordance with local ethics committee indications. Main inclusion criteria were, no concomitant interacting drugs, no hepatic or renal function impairment, self-reported adherence > 95%. Dasatinib PBMC and plasma Ctrough was measured in samples by a validated High Pressure Liquid Chromatography tandem MS detection method. We evaluated the following ABCB1 SNPs: rs1128503, rs2032582 and rs1045642. Genotyping was conducted by real time PCR based allelic discrimination using standard methodology. Statistical analysis was conducted by Mann Whitney or Spearman Rank to assess the effects of weight, age, gender, and dosage on dasatinib intracellular Ctrough. Median value of individual measurements was considered (±SD). Values were expressed as ng/mL. Results Twelve patients met the inclusion criteria. No associations between weight, age, gender, dosage and dasatinib PBMC Ctrough were observed. Despite the low number of patients, significant correlations between PBMC concentrations and PBMC concentrations/dose and ABCB1 SNPs 3435C>T and 1236C>T were observed. Specifically, the median intracellular dasatinib Ctrough in individuals with homozygote mutation allele (TT, n=4) for 1236C>T was lower as compared to patients with wild-type(WT)/heterozygote(ET) genotype (CC/CT, n=8) [599 (±271) vs 1436 (±1670), respectively, p=0. 042]. Similarly, intracellular dasatinib concentrations in individuals with homozygote mutation allele for 3435TT (n=4) and 2677TT (n=2) were lower as compared to patients with WT/ET genotype, with no significant p-value [673 (±324) vs 1436 (±1692), p=0. 089; 673 (±54) vs 1256 (±1599), p=0. 390, respectively], but with a clear trend. This data were significant when intracellular concentrations were corrected with each patient dosage of dasatinib. When we considered patient carriers of at least a homozygote mutation (TT carrier) on SNPs examined (n = 6), intracellular concentrations have been shown to be significantly lower than WT/ET patients [599 (±313) vs 1559 (±1706), p<0. 001, respectively]. Conclusions These findings suggest that ABCB1 SNPs may actually determine an important influence on PBMC exposure. Since the drug fraction reaching the intracellular compartment is the one exerting therapeutic action, these factors could of course exert an influence on the response to therapy as well as on the onset of some toxicity effects. Further clinico-pharmacological studies, with an higher number of patients, are now required to confirm this association and to establish a relationship between this single-nucleotide polymorphisms of the ABCB1 gene and response and side effects observed in individual patients during dasatinib therapy. Disclosures: No relevant conflicts of interest to declare." @default.
• W2563674152 created "2017-01-06" @default.
• W2563674152 creator A5003451849 @default.
• W2563674152 creator A5019949455 @default.
• W2563674152 creator A5021206943 @default.
• W2563674152 creator A5046854142 @default.
• W2563674152 creator A5057818859 @default.
• W2563674152 creator A5070034219 @default.
• W2563674152 creator A5076836884 @default.
• W2563674152 creator A5081880540 @default.
• W2563674152 creator A5090108654 @default.
• W2563674152 date "2012-11-16" @default.
• W2563674152 modified "2023-10-17" @default.
• W2563674152 title "Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib" @default.
• W2563674152 doi "https://doi.org/10.1182/blood.v120.21.4903.4903" @default.
• W2563674152 hasPublicationYear "2012" @default.
• W2563674152 type Work @default.
• W2563674152 sameAs 2563674152 @default.
• W2563674152 citedByCount "0" @default.
• W2563674152 crossrefType "journal-article" @default.
• W2563674152 hasAuthorship W2563674152A5003451849 @default.
• W2563674152 hasAuthorship W2563674152A5019949455 @default.
• W2563674152 hasAuthorship W2563674152A5021206943 @default.
• W2563674152 hasAuthorship W2563674152A5046854142 @default.
• W2563674152 hasAuthorship W2563674152A5057818859 @default.
• W2563674152 hasAuthorship W2563674152A5070034219 @default.
• W2563674152 hasAuthorship W2563674152A5076836884 @default.
• W2563674152 hasAuthorship W2563674152A5081880540 @default.
• W2563674152 hasAuthorship W2563674152A5090108654 @default.
• W2563674152 hasConcept C121608353 @default.
• W2563674152 hasConcept C125418893 @default.
• W2563674152 hasConcept C126322002 @default.
• W2563674152 hasConcept C143998085 @default.
• W2563674152 hasConcept C170493617 @default.
• W2563674152 hasConcept C203014093 @default.
• W2563674152 hasConcept C2776960273 @default.
• W2563674152 hasConcept C2777583451 @default.
• W2563674152 hasConcept C2778461978 @default.
• W2563674152 hasConcept C2778729363 @default.
• W2563674152 hasConcept C2778820342 @default.
• W2563674152 hasConcept C2779536868 @default.
• W2563674152 hasConcept C2780035454 @default.
• W2563674152 hasConcept C3019892230 @default.
• W2563674152 hasConcept C42362537 @default.
• W2563674152 hasConcept C502942594 @default.
• W2563674152 hasConcept C71924100 @default.
• W2563674152 hasConcept C98274493 @default.
• W2563674152 hasConceptScore W2563674152C121608353 @default.
• W2563674152 hasConceptScore W2563674152C125418893 @default.
• W2563674152 hasConceptScore W2563674152C126322002 @default.
• W2563674152 hasConceptScore W2563674152C143998085 @default.
• W2563674152 hasConceptScore W2563674152C170493617 @default.
• W2563674152 hasConceptScore W2563674152C203014093 @default.
• W2563674152 hasConceptScore W2563674152C2776960273 @default.
• W2563674152 hasConceptScore W2563674152C2777583451 @default.
• W2563674152 hasConceptScore W2563674152C2778461978 @default.
• W2563674152 hasConceptScore W2563674152C2778729363 @default.
• W2563674152 hasConceptScore W2563674152C2778820342 @default.
• W2563674152 hasConceptScore W2563674152C2779536868 @default.
• W2563674152 hasConceptScore W2563674152C2780035454 @default.
• W2563674152 hasConceptScore W2563674152C3019892230 @default.
• W2563674152 hasConceptScore W2563674152C42362537 @default.
• W2563674152 hasConceptScore W2563674152C502942594 @default.
• W2563674152 hasConceptScore W2563674152C71924100 @default.
• W2563674152 hasConceptScore W2563674152C98274493 @default.
• W2563674152 hasIssue "21" @default.
• W2563674152 hasLocation W25636741521 @default.
• W2563674152 hasOpenAccess W2563674152 @default.
• W2563674152 hasPrimaryLocation W25636741521 @default.
• W2563674152 hasRelatedWork W1978777017 @default.
• W2563674152 hasRelatedWork W200163820 @default.
• W2563674152 hasRelatedWork W2100041900 @default.
• W2563674152 hasRelatedWork W2155107050 @default.
• W2563674152 hasRelatedWork W2523588288 @default.
• W2563674152 hasRelatedWork W2556047608 @default.
• W2563674152 hasRelatedWork W2572120445 @default.
• W2563674152 hasRelatedWork W2979743675 @default.
• W2563674152 hasRelatedWork W3084350744 @default.
• W2563674152 hasRelatedWork W3204122798 @default.
• W2563674152 hasVolume "120" @default.
• W2563674152 isParatext "false" @default.
• W2563674152 isRetracted "false" @default.
• W2563674152 magId "2563674152" @default.
• W2563674152 workType "article" @default.